| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Outlook Therapeutics, Inc.
13D/A
Amendment 7
OTLK · 69012T305
|
16.4% |
8/14/2026
Event 8/12/2026
|
|||
| GMS Ventures & Investments | 16.4% | ||||
| Sukhtian Ghiath M. | 16.4% | ||||
|
Outlook Therapeutics, Inc.
13D/A
Amendment 6
OTLK · 69012T305
|
22.9% |
6/1/2026
Event 5/28/2026
|
|||
| GMS Ventures & Investments | 22.9% | ||||
| Sukhtian Ghiath M. | 22.9% | ||||
|
Outlook Therapeutics, Inc.
13D/A
Amendment 5
OTLK · 69012T305
|
50.3% |
5/28/2025
Event 5/27/2025
|
|||
| GMS Ventures & Investments | 50.3% | ||||
| Sukhtian Ghiath M. | 50.3% | ||||
|
Outlook Therapeutics, Inc.
13D/A
Amendment 4
OTLK · 69012T305
|
41.6% |
3/12/2025
Event 3/11/2025
|
|||
| GMS Ventures & Investments | 41.6% | ||||
| Sukhtian Ghiath M. | 41.6% | ||||
|
Outlook Therapeutics, Inc.
13D/A
Amendment 3
OTLK · 69012T305
|
38.6% |
1/22/2025
Event 1/17/2025
|
|||
| GMS Ventures & Investments | 38.6% | ||||
| Sukhtian Ghiath M. | 38.6% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.